Group 1 - February macro outlook indicates a favorable macro environment for equity markets, with expectations of strong economic and credit data at the beginning of the year [7][9] - The strategy outlook suggests a transition in market styles, with a focus on growth "rest" and a continued bullish stance while adjusting portfolio structures [9][10] - The quantitative strategy emphasizes investing in small-cap stocks and taking long positions before the Spring Festival [10] Group 2 - The February gold stock selection includes companies from various sectors: - Electronics: Shiyun Circuit, Shengkong Co. - Consumer Electronics: Baiwei Storage - Computing: Yunsai Zhiliang - Communication: Kexin Innovation Source - Non-ferrous Metals: Shengtun Mining, Luoyang Molybdenum - Machinery: Zhonglian Heavy Industry - Coal: Huaibei Mining - Non-bank Financials: Dongfang Securities [12][14] - The rationale for selected stocks includes: - Shiyun Circuit is expected to benefit from emerging fields such as commercial aerospace and intelligent driving, potentially leading to significant growth [13] - Shengkong Co. is positioned to gain from the semiconductor cycle, with demand driven by AI and storage needs [17] - Baiwei Storage is set to capitalize on the AI infrastructure boom, with a focus on domestic market share growth [20] - Yunsai Zhiliang is anticipated to see increased demand for cloud services and IDC, driven by AI advancements [22] - Kexin Innovation Source is expected to achieve breakthroughs in the AI liquid cooling market, enhancing revenue and profitability [26] - Shengtun Mining is projected to improve profitability through copper price increases and strategic acquisitions [31] - Luoyang Molybdenum is expected to benefit from increased copper and cobalt production, alongside new gold mining projects [35] - Zhonglian Heavy Industry is positioned for growth through diversification in machinery sectors and global expansion [40] - Huaibei Mining is highlighted for its high elasticity in coking coal, with price improvements expected in 2026 [46] - Dongfang Securities is set to benefit from regulatory support and potential mergers, enhancing its market position [49]

Investment Rating - The report indicates an "Overweight" rating for the industry, suggesting a positive outlook for the next six months [51]. Core Insights - The report emphasizes the importance of focusing on technology and security, as well as reform and growth, in the industry configuration for 2026. It highlights the need for self-reliance in technology to enhance national security and the importance of deepening reforms to strengthen internal growth resilience [45]. - It identifies key areas of investment interest, including AI capabilities, resource and energy security, and innovative developments in frontier industries such as aerospace, quantum technology, and solid-state batteries [45]. - The report also notes a shift in market sentiment, with a focus on consumer services and non-durable goods, indicating a potential recovery in domestic demand [45]. Market Review - The average daily trading volume for the entire A-share market reached 3.06 trillion yuan, an increase of over 260 billion yuan compared to the previous week [8]. - The report highlights that large-cap stocks outperformed during the week, with significant movements in various indices [12][14]. Market Style Performance - The report notes that small-cap stocks showed a relative decline against large-cap stocks, indicating a shift in market dynamics [14]. - Growth stocks are currently underperforming compared to value stocks, reflecting a challenging environment for growth-oriented investments [17]. Participant Performance - The report shows that social security and northbound trading indices outperformed private equity heavy stocks, with the social security heavy index declining by 1.96% [20]. Industry Trends - The report identifies strong trends in the technology sector, particularly in AI and related applications, as well as in energy security and resource management [38]. - Upcoming industry events, such as the Asian Virtual Reality XR Industry Exhibition and the 2026 AI Conference, are expected to influence market dynamics and investment opportunities [42][44].

Core Viewpoint - The article emphasizes the commitment of Haikou to accelerate the construction of the Hainan Free Trade Port, aiming to position it as a significant gateway for China's new era of opening up to the world [1][2]. Group 1: Economic Development - Haikou will implement the spirit of the provincial two sessions, promoting a pioneering and hardworking attitude to achieve economic and social development goals [2]. - The city aims to expand its openness by fully implementing free trade port policies and transforming policy dividends into development momentum [2]. - There is a focus on deepening cooperation with countries and regions involved in the Belt and Road Initiative and exploring new collaborative scenarios with the Guangdong-Hong Kong-Macao Greater Bay Area [2]. Group 2: Industry Growth - The development strategy includes fostering four types of industries: strategic support, free trade characteristics, future emerging, and empowerment guarantee industries [2]. - Key sectors such as biomanufacturing, hydrogen energy, and brain-computer interface industrialization will be supported, along with optimizing and upgrading leading industries [2]. - The city will promote high-quality development in key areas like airport economy, port industries, and headquarters economy, while exploring Transit-Oriented Development (TOD) models [2]. Group 3: Reform and Innovation - There will be a focus on deepening reform and innovation in key areas, aiming to produce more globally influential and recognizable institutional innovations [2]. - The city plans to enhance standardized and non-standardized services, extending the approach of "solving one issue" to "handling a category of issues" to create a first-class business environment [2]. Group 4: Social Welfare - Haikou will invest more policies, funds, and resources into public welfare, emphasizing inclusive, foundational, and safety-net social construction [3]. - The city aims to advance urban health checks and urban renewal in a coordinated manner [3].

行 机械设备 2026 年 01 月 31 日 业 研 究 机械设备 超声脑机接口启新篇，中国方案破解脑病治疗困局 投资要点： "十五五"重点赛道，脑机接口市场规模有望快速增长 根据 precedence research，2024 年全球脑机接口市场规模约为 26.2 亿美元，预计 2025 年将达到 29.4 亿美元，到 2034 年有望增长至 124 亿美元，十年间复合年增长率为 17.35%；据工信微报，2024 年中国脑 机接口市场规模为 32.0 亿元，预计到 2028 年将达 61.4 亿元。《中共 中央关于制定国民经济和社会发展第十五个五年规划的建议》提出前 瞻布局未来产业，推动脑机接口等成为新的经济增长点。这些产业蓄 势发力，未来 10 年将再造一个中国高技术产业。 建议关注 岩山科技、汉威科技、三博脑科、创新医疗、东方中科、翔宇医 疗、熵基科技、诚益通、伟思医疗、麦澜德、爱朋医疗、倍益康等。 风险提示 证 市场竞争加剧、政策支持力度不及预期、技术研发及新产品开发 不利、脑机产品造成病患受伤等风险 技术突破创新，超声精准打开血脑屏障 行 业 定 期 报 告 近日，复旦大学联合华山医院在国家重 ...

行 机械设备 2026 年 01 月 31 日 业 研 究 机械设备 超声脑机接口启新篇，中国方案破解脑病治疗困局 投资要点： 技术突破创新，超声精准打开血脑屏障 行 业 定 期 报 告 近日，复旦大学联合华山医院在国家重点研发计划项目启动会上， 发布国内首例采用自主研制超声诊疗一体化装置"UltraBrainPad"的临 床试验成果。该半侵入式技术为全球第三种方案，通过手持式探头结 合 AI 图像识别，3 分钟即可打开胶质母细胞瘤患者血脑屏障，药物浓 度平均提升 8 倍，6 小时后屏障自动关闭，操作便捷、成本可控且安全 性优于国际水平，成功破解传统技术感染风险高、精度不足等难题。 赛道拓展赋能，惠及多种脑病治疗场景 作为国家重点研发计划项目，该技术已启动复发胶质母细胞瘤临 床研究，未来将打造超声脑机接口新赛道。除脑肿瘤药物治疗外，其 科研成果还将向神经调控、脑机融合方向转化，有望为阿尔兹海默病、 头痛、失眠等多种脑病提供全新治疗路径，凭借基层可及的优势，让 更多患者受益于这一"中国方案"。 岩山科技、汉威科技、三博脑科、创新医疗、东方中科、翔宇医 疗、熵基科技、诚益通、伟思医疗、麦澜德、爱朋医疗、倍益康等。 ...

Investment Rating - The industry investment rating is "Positive" and maintained [8] Core Insights - On January 28, the National Medical Products Administration approved two medical device industry standard revision projects related to brain-computer interface technology, which is expected to accelerate the commercialization of the brain-computer interface industry [5][12] - The rapid approval of these standards reflects the urgent need for establishing industry standards in the brain-computer interface sector, which is currently transitioning from technological research to clinical application and industrialization [12] - The brain-computer interface industry is experiencing significant technological breakthroughs, with a total of 2,041 related patents in China as of early 2026, of which over 90% are invention patents [12] Summary by Sections Event Description - The National Medical Products Administration has initiated two standard revision projects to support the high-quality development of medical devices utilizing brain-computer interface technology [5][12] Event Commentary - The approval of these standards is expected to provide a critical push for the development of brain-computer interfaces, facilitating their transition from laboratory research to clinical applications [12] - The industry is currently at a pivotal stage, with a growing number of patents and a need for standardized regulations to support its growth [12] - The government has recognized brain-computer interfaces as a key future industry, aiming to enhance their commercialization and integration into the healthcare system [12]

Group 1 - OPEC+ will hold a monthly meeting to discuss oil production policies [2] - The U.S. will release January ADP employment data and the European Central Bank will announce its interest rate decision [2] - Major companies such as Alphabet, Qualcomm, and Amazon are set to disclose their earnings [2][4] Group 2 - The China National Bureau of Statistics will publish January CPI and PPI data [4] - The International Energy Agency (IEA) will release its monthly oil market report [4] - The U.S. Energy Information Administration (EIA) will provide its monthly short-term energy outlook report [4]

Major Events - OPEC+ will hold a monthly meeting to discuss oil production policies [2] - The domestic refined oil price adjustment window will open in February 2026 [2] - The U.S. will release January ADP employment data, and the European Central Bank will announce its interest rate decision [2] Important Data - China's January CPI and PPI will be published, along with the IEA's monthly oil market report [4] - The U.S. will release its January PPI data [4] - The EIA will publish its short-term energy outlook report [4] Key Companies - AMD will disclose its performance results [4] - Nvidia and Baidu are also set to release their earnings reports [5] - Apple will hold its annual shareholder meeting [5]

Core Insights - The global biopharmaceutical industry is still experiencing a "capital winter" in 2025, undergoing deep structural adjustments and facing a critical period of transformation and reconfiguration [1] - Shanghai's biopharmaceutical industry has shown resilience and steady growth, with manufacturing output reaching 209.9 billion yuan, driven by a shift towards innovative and high-quality enterprises [2] Structural Optimization: Full-Chain Innovation Development - The shift from generic drugs to innovative drugs is exemplified by the success of Silver诺药业, which launched the first original human long-acting GLP-1 drug in China, benefiting many patients with type 2 diabetes [3] -艾力斯医药's revenue surged from 530 million yuan in 2021 to 3.56 billion yuan in 2024, with a compound annual growth rate of 88.6% [3] - In 2025, Shanghai approved nine domestic Class 1 innovative drugs, ranking second nationally, and accounted for 33% of business development transactions in the country, leading the nation [3] Policy Support and Innovation Ecosystem - Over the past five years, Shanghai has approved 32 domestic Class 1 innovative drugs, maintaining its position as a leader in the industry [4] - The city has implemented forward-looking policies, such as the drug listing license holder system, to address the challenges of "having technology but no factory" [4] New Growth Areas: Diverse Expansion - Shanghai is emerging as a leader in brain-computer interface technology, with nearly 30 registered companies and significant funding in this sector [5] - The city also leads in cell and gene therapy, with 57% of the country's products launched between 2021 and September 2025 [5] AI-Driven Pharmaceutical Innovation - AI-driven drug development is reshaping research paradigms, with 英矽智能 discovering 27 preclinical candidates, 13 of which have received clinical trial approvals [6] - By the end of 2025, 英矽智能 is expected to become the first AI pharmaceutical company listed on the Hong Kong Stock Exchange, raising a record 2.277 billion HKD [6] Global Value Co-Creation - Shanghai's innovative drugs are increasingly entering global markets, transitioning from a one-time sale model to a co-creation model, enhancing their bargaining power [8] - 和铂医药's licensing transactions exceeded 7 billion USD in 2025, reflecting the growing international recognition of Shanghai's innovative drug development capabilities [8] Globalization of Innovative Medical Devices - 联影医疗 has launched over 140 proprietary products, entering more than 90 countries and regions, showcasing the global reach of Shanghai's innovative medical devices [9] - The city has established supportive policies for innovative drugs and devices that achieve registration and sales in multiple countries, providing up to 10 million yuan in support for qualifying projects [9]

Core Viewpoint - The company anticipates a net loss for the fiscal year 2025 due to various factors including industry adjustments, increased R&D investments, and expected impairment losses [1][2]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025, with an expected net profit being negative [1]. - The company has communicated with its accounting firm regarding the performance forecast, and there are no discrepancies between the two parties [1]. Group 2: Reasons for Performance Changes - The primary reasons for the anticipated loss include delays in contract signing due to industry client adjustments and cyclical fluctuations, leading to reduced revenue [2]. - The company has invested approximately 930 million yuan in R&D to enhance its competitiveness in emerging fields such as chips, satellite internet, and 6G technology, which has increased expenditures [2]. - Expected sales and collections for 2025 did not meet projections, prompting the company to propose impairment losses of approximately 220 million yuan for goodwill and 250 million yuan for receivables [2]. Group 3: Strategic Initiatives - The company is actively pursuing market share and expanding into international markets while focusing on both military and civilian products [3]. - In the satellite internet sector, the company has achieved a full industry chain layout, including chips, terminals, and system operations [3]. - The company aims to enhance operational efficiency and economic benefits by targeting new production capabilities and military combat capabilities, while also expanding into civilian and international markets [3]. Group 4: Contract Overview - The company has signed a contract worth approximately 335 million yuan with a special institutional client, which is expected to positively impact revenue and profit [7][14]. - The contract involves wireless communication and Beidou navigation products, and it is expected to account for 6.81% of the company's audited revenue for the most recent fiscal year [11][14]. - The execution of the contract will not affect the company's business independence, as it will not create dependency on the counterparty [16].